and here is the really big news for today. POH is adding Topical OXYCODONE gel to is formidible PAIN portfolio. In a world first they can deliver OXY straight to the nerves which can be used for main management in severe conditions like Shingles, Neuropathey and bad backs.
If you haven't taken any notice of what POH have been up too, its time to have a look. TYhere is a lot of value in this Pain Portfolio that is not reflected in the SP.
A very safe project with many years of good science to back it up. And Phase 3 OXYPATCH starting later this year a lot of attention will come to this stock..
Phosphagenics Further Expands Pain Portfolio
? Topical oxycodone opportunity
? Phosphagenics has achieved outstanding results from pre-clinical trial
? US$4 billion global topical pain market
? Topical oxycodone to join oxycodone and oxymorphone opioid patches
in 2013 clinical trials
20 February 2013, Melbourne, Australia: Melbourne drug delivery technology
company, Phosphagenics Limited (ASX: POH, OTCQX: PPGNY), has completed a
pre-clinical study demonstrating that its oxycodone/TPM® technology can reduce local
pain without the need to deliver oxycodone into the bloodstream. This discovery has
significant commercial implications and the Company intends to commence clinical
trials in Quarter 3 of 2013.
These trials would be additional to the current oxymorphone and oxycodone patch
trials referred to in recent announcements. This product represents a further extension
to Phosphagenics’ pain product development program.
The finding stems from TPM’s unique ability to deliver molecules in a targeted manner
either into the skin or through the skin into the bloodstream, by modifying the
formulation. Phosphagenics has formulated TPM® to deliver compounds into the skin
for its many topical dermatological and personal care applications. In the pre-clinical
study on oxycodone/TPM® for localised pain, TPM® was formulated to deliver
oxycodone into the localised area of application, without spillage into the blood. This
potential new application of oxycodone to local pain further broadens the Company’s
pain franchise.
The pre-clinical study in an appropriate pain model demonstrated a significant
reduction in pain after topical application of the oxycodone/TPM® formulation, as
compared to a control. The investigation also found the opioid worked rapidly and did
not enter the bloodstream.
A topical opioid able to act directly on inflamed tissue, without delivery into the systemic
circulation, could eliminate all side effects associated with ingestion of the oral dosage
form. It would therefore represent a much safer dosage form, and may be appropriate
for localised pain indications that have traditionally proven very difficult to treat. These
include both post-herpetic neuralgia/shingles and diabetic neuropathy.
Phosphagenics’ CEO, Dr Esra Ogru, said the company was keen to expand its pain
portfolio and progress further trials of topical TPM® oxycodone technology.
Page 2 of 2
There is no topical opioid product on the market and sales of non-opioid pain drugs
prescribed for localised pain exceed US$4 billion annually. Endo Pharmaceutical’s
market leading topical pain product, Lidoderm™, is used to treat neuropathic pain but
belongs to a different class of non-opioid analgesic compounds.
Dr Ogru said: “Delivering a powerful opioid like oxycodone topically has never been
achieved commercially. It has been widely assumed that opioids can only treat pain by
systemic delivery, that is, via the blood stream. Our study confirms more recent
findings that opioid receptors are up-regulated in tissue in response to pain, particularly
pain associated with inflammation.”
Dr Ogru added: “There is no other company in the area of transdermal delivery of pain
drugs progressing multiple products with multiple applications. This potential new
application of oxycodone to local pain further broadens our pain franchise. We remain
committed to our strategy of building a first class pain portfolio comprising a series of
compounds with the ability to manage all levels of pain, with various application
methods. Underpinning this entire platform is our TPM® delivery technology which we
are continuously demonstrating enables superior delivery of many compounds.”
Release of the conclusions from this pre-clinical investigation coincides with
Phosphagenics’ two further clinical trials of its TPM® opioid pain patch technology for
the systemic treatment and management of chronic pain using oxycodone and
oxymorphone.
The combined US market for these two compounds, currently administered orally,
exceeds 70 per cent of the $5 billion extended-release opioid market.
While oxycodone dominates the market, sales of oxymorphone grew by over 17 per
cent in 2012 to become the third largest opioid in the category.
Ends
Enquiries:
Dr Esra Ogru David Segal
Chief Executive Officer Investor Relations Manager
Phosphagenics Limited Phosphagenics Limited
+61 3 9565 1119 +61 3
- Forums
- ASX - By Stock
- biotech thread - wednesday 20th february
biotech thread - wednesday 20th february , page-3
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)